CTMX-2009-002

A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)

Condition: Negative Breast Cancer | Last Updated: 3 Jun 2022 | Status: enrolling

View Full Study